Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Decatur Memorial Hospital
mi
from
Decatur, IL
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Ingalls Memorial Hospital
mi
from
Harvey, IL
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology Hematology, PA - Minneapolis
mi
from
Minneapolis, MN
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology Hematology, PA - Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of California Davis Comprehensive Cancer Center P2C
mi
from
Sacramento, CA
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of California Davis Comprehensive Cancer Center P2C
mi
from
Sacramento, CA
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
City of Hope South Pasadena
mi
from
South Pasadena, CA
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope South Pasadena
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
UC Comprehensive Cancer Center at Silver Cross
mi
from
New Lenox, IL
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
UC Comprehensive Cancer Center at Silver Cross
mi
from
New Lenox, IL
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Tom Baker Cancer Centre
mi
from
Calgary,
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Tom Baker Cancer Centre
mi
from
Calgary,
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota Community Oncology Research Consortium
mi
from
Saint Louis Park, MN
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota Community Oncology Research Consortium
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Penn State Children's Hospital
mi
from
Hershey, PA
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Penn State Children's Hospital
mi
from
Hershey, PA
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital
mi
from
Aurora, CO
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Healthy Bodies, Healthy Kids
Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Healthy Bodies, Healthy Kids
Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
A Phase III Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy in Patients With Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
A Phase III Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy in Patients With Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
A Phase III Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy in Patients With Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
A Phase III Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy in Patients With Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
A Phase III Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy in Patients With Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pisa
mi
from
Pisa,
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
A Phase III Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy in Patients With Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pisa
mi
from
Pisa,
Click here to add this to my saved trials
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
Effects of Intervention With the Glucagon-like Peptide 1 (GLP-1) Analog Liraglutide Plus Metformin Versus Metformin Monotherapy in Overweight/Obese Women With Metabolic Defects and Recent History of Gestational Diabetes Mellitus (GDM)
Status: Enrolling
Updated:  12/31/1969
Woman's Hospital
mi
from
Baton Rouge, LA
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
Effects of Intervention With the Glucagon-like Peptide 1 (GLP-1) Analog Liraglutide Plus Metformin Versus Metformin Monotherapy in Overweight/Obese Women With Metabolic Defects and Recent History of Gestational Diabetes Mellitus (GDM)
Status: Enrolling
Updated: 12/31/1969
Woman's Hospital
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Kirklin Clinic at Acton Road
mi
from
Birmingham, AL
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Kirklin Clinic at Acton Road
mi
from
Birmingham, AL
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology - Deer Valley Center
mi
from
Phoenix, AZ
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology - Deer Valley Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Services Foundation
mi
from
Scottsdale, AZ
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Services Foundation
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Auburn
mi
from
Auburn, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Auburn
mi
from
Auburn, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Alta Bates Summit Medical Center-Herrick Campus
mi
from
Berkeley, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Alta Bates Summit Medical Center-Herrick Campus
mi
from
Berkeley, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
mi
from
Cameron Park, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
mi
from
Cameron Park, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Eden Hospital Medical Center
mi
from
Castro Valley, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Eden Hospital Medical Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Roseville
mi
from
Roseville, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Roseville
mi
from
Roseville, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center-Pacific Campus
mi
from
San Francisco, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center-Pacific Campus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center at Parnassus
mi
from
San Francisco, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center at Parnassus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Vacaville
mi
from
Vacaville, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Vacaville
mi
from
Vacaville, CA
Click here to add this to my saved trials